Hi-Tech Pharmacal (HITK) Tops Q2 Earnings Views
More News related to HITK
- Hi-Tech Pharmacal's ECR Subsidiary Signs Exclusive Agreement to Commercialize Sleep Aid in Oral Spray Form
- Semi-Annual Changes to the NASDAQ Biotechnology Index
- Hi-Tech Pharmacal to Present at the 20th Annual Oppenheimer Healthcare Conference
- FTN Equity Downgrades Hi-Tech Pharmacal (HITK) from Buy
- Unusual 11 Mid-Day Movers 9/9: ENCO, VVUS, CLZR, HITK, DPTR Higher; OPXA, LRN, ROSG, ELOS Lower
More News related to Earnings
- Dyax (DYAX) Receives FDA Approval of KALBITOR(R) for Treatment of Acute Attacks of Hereditary Angioedema
- Santarus (SNTS) Earns $20 Million Milestone on FDA Approval for NDA of ZEGERID
- Santarus (SNTS) Jumps Ahead of Expected News
- Hemispherx Biopharma (HEB) Receives Letter for Ampligen From US FDA; FDA Cannot Approve Application in Present Form
- Hemispherx (HEB) Falls 30% as FDA Recommends Another Ampligen Study, Says Can't Approve Application in Present Form
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) reports Q2 EPS of $0.09, 3 cents better than the analyst estimate of $0.06. Revenue for the quarter was $25.1 million, versus the consensus of $22.50 million. (only 1 analyst covers the stock)
Hi-Tech Pharmacal Co., Inc. develops, manufactures, markets, and sells generic, prescription, over-the-counter (OTC), and nutritional products in liquid and semisolid dosage forms in the United States.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
